| 2026-07-29 | Deck | Earnings presentation · Q2 2026 · Jul 2026 |
| 2026-07-29 | Press release | TEVA DELIVERS STRONG Q2 RESULTS AND RAISES OUTLOOK FOR ALL THREE KEY INNOVATIVE BRANDS, REFLECTING CONTINUED EXECUTION OF ITS PIVOT TO GROWTH STRATEGY · 2026 |
| 2026-07-29 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-29 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-09 | Press release | Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) fo |
| 2026-07-07 | Press release | Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following |
| Transcript | Q2 FY26 earnings call transcript |
| 2026-06-18 | Press release | Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome |
| 2026-06-10 | Press release | Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Gro |
| 2026-06-08 | Press release | Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight |
| 2026-06-05 | Press release | Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablet |
| 2026-05-28 | 8-K | Form 8-K, Item 5.07 |
| 2026-04-29 | Press release | TEVA DELIVERS STRONG Q1 2026 RESULTS DRIVEN BY INNOVATIVE PORTFOLIO GROWTH AND DISCIPLINED EXECUTION |
| 2026-04-29 | Deck | Earnings presentation · Q1 2026 · Apr 2026 |
| 2026-04-29 | Deck | Q1 2026 Financial Results |
| 2026-04-29 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-29 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-03-31 | Proxy | Definitive proxy statement |
| 2026-02-03 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-01-31 | Transcript | Q4 FY25 earnings call transcript |
| 2026-01-28 | Deck | Earnings presentation · Q4 2025 · Apr 2026 |
| 2026-01-28 | Press release | TEVA INNOVATIVE PORTFOLIO AND CONSISTENT EXECUTION OF PIVOT TO GROWTH STRATEGY DELIVER THIRD CONSECUTIVE YEAR OF GROWTH ; PIPELINE POSITIONED TO UNLOCK SIGNIFICANT VALUE POTENTIAL · Q4 2025 |
| 2026-01-28 | Deck | Quarterly report · Q4 2025 · Jan 2026 |
| 2026-01-28 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-27 | Deck | Q4 2025 Fact Sheet |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |
| 2025-12-11 | 8-K | Form 8-K, Item 1.01 |
| 2025-11-05 | Deck | Earnings presentation · FY 2025 · Nov 2025 |
| 2025-11-05 | Deck | Innovative Portfolio Driving Q3 2025 Growth |
| 2025-11-05 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-05 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-11-03 | Deck | Q3 2025 Fact Sheet |
| 2025-09-25 | Supplement | Q3 2025 Aide Memoire |
| 2025-07-30 | Deck | Earnings presentation · Q2 2025 · Jul 2025 |
| 2025-07-30 | Deck | Q2 2025 Financial Results |
| 2025-07-30 | 8-K | Form 8-K, Item 2.02 results |
| 2025-07-30 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-07-29 | Deck | Q2 2025 Fact Sheet |
| 2025-06-26 | Supplement | Q2 2025 Aide Memoire |
| 2025-06-05 | 8-K | Form 8-K, Item 5.07 |